Drugs / interleukin-12
interleukin-12
also known as
IL-12 · rhIL-12 · Recombinant Human Interleukin-12 · NSC # 672423 · pIL-12 · recombinant interleukin-12
Trials 24
News releases announcing trial results or a regulatory action · 107
| Date | Issuer | Release |
|---|---|---|
| 2026-05-18 | Kolon Life Science | Results [보도자료] 코오롱생명과학, KLS-3021 美 ASGCT 구두 발표…삼중음성유방암 항암효과 및 장기 면역기억 형성 확인 kolonls.co.kr ↗
종양이 일정 크기에 도달한 이후 KLS-3021을 종양 내 단회 투여한 결과, 용량 의존적인 종양 성장 억제 효과가 확인됐으며, 고용량군에서는 완전관해(CR)도 관찰됐다. |
| 2026-04-27 | Kolon Life Science | Results [보도자료] 코오롱생명과학, KLS-3021 피부암 연구 국제학술지 게재…전이암 억제 및 항암 면역환경 개선 가능성 제시 kolonls.co.kr ↗
연구 결과, KLS-3021은 cSCC 세포주에서 정상세포 대비 높은 암세포 선택적 세포독성 및 바이러스 증식 능력을 나타냈다. |
| 2026-04-08 | Trogenix ltd | Results Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model trogenix.com ↗ |
| 2026-01-30 | PDS Biotechnology Corp. | Results PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI pdsbiotech.com ↗
Results showed median progression-free survival (“PFS”) of 9.6 months (range: 4.3–32.2 months) for the combination therapy in mCRPC patients. |
| 2025-12-07 | Akeso | Regulatory 康方5个新药所有适应症全部谈判成功，纳入国家医保：2个首创双抗新增一线适应症及3个新药首次进医保 akesobio.com ↗ |
| 2025-11-07 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting werewolftx.com ↗
The new preclinical data presented at SITC expand on this foundation by demonstrating two novel therapeutic strategies: a sequential regimen designed to safely harness the complementary immune mechanisms of IL-12 and IL-2, and the development of masked, conditional T cell engagers (INDUCER molecules) designed to mitigate systemic toxicities. |
| 2025-10-17 | Kolon Life Science | Results [보도자료] 코오롱생명과학, ‘2025 유럽종양학회’ 포스터 발표…KLS-3021 전립선암 대상 전임상 결과 첫 공개 kolonls.co.kr ↗
이번 전립선암 동소이식 종양모델을 사용한 항암 효능 평가에서 KLS-3021의 단 1회 투여로 종양 크기가 유의하게 감소한 것으로 나타났으며, 대조군 항암제인 도세탁셀(docetaxel) 대비해서도 우수한 항암 효과가 관찰됐다. |
| 2025-09-22 | Imunon | Results IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift imunon.com ↗
Positive shift in the local TME to favorable immune stimulatory T cell ratios in the majority of participants treated with IMNN-001, including favorable ratios of CD8+/T regulatory (Treg) cells, CD8+/IDO+ cells, and CD8+/CD4+ cells. |
| 2025-05-20 | Kolon Life Science | Results [보도자료] 코오롱생명과학, 美 유전자세포치료학회(ASGCT)서 ‘KLS-3021’ 피부 편평세포암 전임상 결과 포스터 발표 kolonls.co.kr ↗
발표에 따르면 KLS-3021은 사람 피부 편평세포암 세포주에서 정상 사람 표피 각질 세포 대비 높은 선택적 세포 독성을 나타냄과 동시에 종양세포 내에서 활발하게 복제해 암세포를 효과적으로 사멸시키는 것으로 확인됐다. |
| 2025-04-29 | Microbiotica Ltd | Results Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma microbiotica.com ↗
These assays have demonstrated that three of the MB097 strains induce dendritic cells to produce high levels of IL-12, which in turn stimulates Cytotoxic T Lymphocytes and NK cells with potent tumour cell killing activity. |
| 2025-04-18 | Akeso | Regulatory 康方生物爱达罗®（依若奇,IL-12/IL-23）治疗中重度斑块状银屑病适应症获批上市 akesobio.com ↗
2025年4月18日，康方生物（9926.HK）欣然宣布，公司独立自主研发的爱达罗®（依若奇单抗，IL-12/IL-23“双靶向”单克隆抗体）获得国家药品监督管理局（NMPA）批准上市，适用于中重度斑块状银屑病成人患者的治疗. |
| 2025-02-19 | Imunon | Results IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer imunon.com ↗
Results demonstrated a 20% increase in IL-12 levels in women treated with IMNN-001 (100 mg/m 2 administered intraperitoneally weekly) plus standard-of-care (SoC) neoadjuvant and adjuvant chemotherapy (NACT) compared to IL-12 levels in women treated with IMNN-001 (79 mg/m 2 ). |
| 2024-12-10 | Imunon | Results IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 imunon.com ↗
Median OS increased from 11 to 13 months in IMNN-001 treatment group based on latest data analysis |
| 2024-11-07 | Imunon | Results IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting imunon.com ↗
IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone |
| 2024-11-05 | Cellectis S.A. | Results Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting cellectis.com ↗ |
| 2024-08-27 | Transgene | Results Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC transgene.com ↗
The JITC paper reports that in addition to consistent multiplication and propagation of TG6050 in tumor cells, functional transgenes are expressed in the tumor with a sustained intratumoral accumulation of IL-12 and anti-CTLA-4 antibody. |
| 2024-04-07 | Geneos Therapeutics | Results Geneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine geneostx.com ↗
The study met its primary endpoints of safety and immunogenicity and its secondary endpoint of efficacy based on observed response rate (ORR). |
| 2024-02-13 | FibroBiologics | Results FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases fibrobiologics.com ↗ |
| 2023-10-31 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting iovance.com ↗
Tumor infiltrating lymphocytes (TIL) with inducible and membrane-bound IL-12 exhibit superior antitumor activity in vitro |
| 2023-10-13 | Akeso | Results 康方IL-12/IL-23单抗依若奇治疗中重度银屑病Ⅲ期临床结果发表于EADV 2023 akesobio.com ↗ |
| 2023-09-27 | Iovance Biotherapeutics, Inc. | Results Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting iovance.com ↗
Tumor infiltrating lymphocytes (TIL) with inducible and membrane-bound IL-12 exhibit superior antitumor activity in vitro |
| 2023-08-22 | Geneos Therapeutics | Results Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer geneostx.com ↗
To date, among 32 evaluable patients from the first 34 enrolled, by RECIST1.1 the study has achieved 3 complete responses, 7 partial responses, 9 stable disease and 13 progressive disease. |
| 2023-04-18 | Zymeworks BC Inc. | Results Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting zymeworks.com ↗
ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity |
| 2023-03-13 | InMed Pharmaceuticals Inc. | Results InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions inmedpharma.com ↗
Results demonstrate these rare cannabinoids significantly blocked inflammation by reducing the release of tested pro-inflammatory interleukins, including IL-1β, IL-8, IL-12, IL-31, IL-10 and tumor necrosis factor (TNF-β). |
| 2022-12-14 | Geneos Therapeutics | Results Geneos Therapeutics Announces Another Complete Response in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer geneostx.com ↗
Overall response rate by RECIST 1.1 is 30.4% in the evaluable patients consisting of three complete responses, four partial responses, six stable disease, and ten progressive disease. |
| 2022-11-10 | Cellectis S.A. | Results Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022 cellectis.com ↗
TGFBR2 knock-out (KO) circumvents the inhibitory effects of TGFβ1, and IL-12 release follows CAR T-cell activation pattern restricting it to the tumor site for increased safety. |
| 2022-11-09 | Immorna Biotherapeutics, Inc. | Regulatory 嘉晨西海自复制RNA癌症治疗药物JCXH-211 正式获得NMPA批准在中国大陆开展临床试验 immorna.com ↗
2022年11月09日，嘉晨西海生物技术有限公司（以下简称“嘉晨西海”），一家专注于多种RNA技术平台开发治疗性药物和预防性疫苗的生物技术公司，宣布其自主研发的创新药物JCXH-211注射液已获得中国国家药品监督管理局（NMPA）批准开展I期临床试验，用于晚期恶性实体瘤治疗。 |
| 2022-11-07 | Geneos Therapeutics | Results Geneos Therapeutics Announces Positive Clinical Data for Personalized Therapeutic Cancer Vaccines in Ongoing Liver Cancer Trial geneostx.com ↗
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced positive safety and efficacy data from the first 24 patients (23 evaluable) enrolled in GT-30. |
| 2022-11-07 | Obsidian Therapeutics, Inc. | Results Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform and Pipeline at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022 obsidiantx.com ↗
Preclinical data highlight numerous pipeline advancements: cytoTIL15™ cells armed with combination-cytokines modulate the tumor microenvironment (TME); spatial profiling of cytoTIL15 cells in PDX models provides greater mechanistic understanding of cell-killing function; and IL12 armored T-cells with precise regulation show anti-tumor activity in solid tumor models. |
| 2022-06-21 | Imunon | Results Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer imunon.com ↗
The DSMB also determined that safety is satisfactory with an acceptable risk/benefit, and that weekly doses of GEN-1 were well tolerated during a course of treatment that is given over six months in combination with standard neoadjuvant chemotherapy. |
| 2022-04-14 | Imunon | Results Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting imunon.com ↗
This larger than expected effect size led to a decrease in the number of planned patients for Celsion’s subsequent Phase II trial and was used in support of Fast Track Designation from the U.S. Food and Drug Administration (FDA) received in February 2021 . |
| 2022-02-17 | Imunon | Results Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer imunon.com ↗
The DSMB also determined that safety is satisfactory with an acceptable risk/benefit, and that patients tolerate up to 17 doses of GEN-1 during a course of treatment that lasts up to six months. |
| 2021-12-01 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting werewolftx.com ↗
interleukin-12 (IL-12) and interferon-α (IFNα) INDUKINETM molecules inhibited syngeneic lymphoma tumor growth in mice, induced anti-tumor immune responses and were tolerated in non-human primates. |
| 2021-11-12 | Xencor, Inc. | Results Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting xencor.com ↗
These potency-reduced IL12-Fc fusions demonstrated significant anti-tumor activity in vivo, concurrent with activation and proliferation of CD8+ T cells and with interferon gamma production. |
| 2021-07-29 | Imunon | Results Results of Celsion’s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research imunon.com ↗ |
| 2021-07-19 | Imunon | Results Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer imunon.com ↗
The DSMB also determined that safety is satisfactory with an acceptable risk/benefit, and that patients tolerate up to 17 doses of GEN-1 during a course of treatment that lasts up to six months. |
| 2021-06-03 | Geneos Therapeutics | Results Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program geneostx.com ↗
The best overall response by the data cut-off date consisted of 3 patients achieving a partial clinical response (PR); 4 patients demonstrated stable disease (SD); and 3 patients had progressive disease (PD); representing an overall response rate (ORR) of 3/10 (30%) and a disease control rate of 7/10 (70%). |
| 2021-05-14 | Senti Biosciences | Results Small-molecule-regulated Gene Circuit for Controlling Cytokine Expression in Cell Therapies sentibio.com ↗
Regulator Dial enabled dose dependent and reversible IL-12 production in vivo |
| 2021-04-10 | Xencor, Inc. | Results Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021 xencor.com ↗
IL12 heterodimeric Fc-fusions engineered for reduced potency exhibit strong anti-tumor activity and improved therapeutic index compar |
| 2021-04-01 | Imunon | Results Poster on Celsion Corporation’s Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer imunon.com ↗
Company reports further strengthening of R0 resection results in patients treated with GEN-1 |
| 2021-02-25 | Imunon | Results Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores imunon.com ↗
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement |
| 2020-11-19 | Alaunos Therapeutics | Results Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for Neuro-Oncology Annual Meeting alaunos.com ↗
First Data from Ongoing Phase 1/2 study of Controlled IL-12 Monotherapy Demonstrate Promising Safety Profile in Patient with DIPG |
| 2020-11-10 | GrandPharma (China) Co., Ltd. | Results 远大医药联营公司OncoSec之核心产品TAVO取得重要研发进展 治疗耐药转移性黑色素瘤注册性临床试验公布的中期数据远超主要终点 grandpharm.com ↗
据了解在本次试验中，临床疗效方面，ORR达到30%，远高于临床试验预期的独立影像评估的ORR主要终点20%；完全缓解率为6%，9%的患者目标病变完全消除，中位持续反应时间为12.2个月。 |
| 2020-11-09 | Xencor, Inc. | Results Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting xencor.com ↗ |
| 2020-09-14 | Alaunos Therapeutics | Regulatory Ziopharm Oncology Granted Rare Pediatric Disease Designation for Controlled IL-12 for the Treatment of DIPG alaunos.com ↗
We are delighted to have received the Rare Pediatric Disease Designation for Controlled IL-12 from the FDA. |
| 2020-06-22 | Xencor, Inc. | Results Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II xencor.com ↗
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new preclinical data from three XmAb ® 2+1 bispecific antibody programs and its IL-12-Fc cytokine program during the second session of the American Association for Cancer Research (AACR) Virtual Annual Meeting. |
| 2020-05-29 | Alaunos Therapeutics | Results Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology alaunos.com ↗
There is evidence of immune-mediated anti-tumor effects, with serial MRIs showing pseudoprogression and one new PR, in addition to the PR previously reported |
| 2020-05-29 | Imunon | Results Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer imunon.com ↗
Based on favorable safety data from 15 randomized patients, the DSMB has recommended that the Phase II portion of the OVATION Study proceed with the dose of 100 mg/m 2 . |
| 2020-03-23 | Imunon | Regulatory Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency imunon.com ↗
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended that GEN-1 be designated as an orphan medicinal product for the treatment of ovarian cancer. |
| 2020-02-06 | Imunon | Results Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer imunon.com ↗
Celsion Corporation (NASDAQ: CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its initial safety review of data from the first fifteen patients treated with the first four neoadjuvant doses of GEN-1 at 100 mg/m² in the ongoing Phase I/II OVATION 2 Study. |
| 2019-11-23 | Alaunos Therapeutics | Results Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting alaunos.com ↗
Immune-mediated pseudoprogression followed by reduction in tumor burden observed in both monotherapy and combination studies with Controlled IL-12 |
| 2019-11-13 | Cellectis S.A. | Results Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications cellectis.com ↗
We have essentially transformed the current T-cells used today into precise and powerful micro-robots that can spray IL-12 specifically onto cancer cells |
| 2019-11-05 | Imunon | Results Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer imunon.com ↗
Based on the DSMB's recommendation, the study will continue as planned and the Company will proceed with completing enrollment in the Phase I portion of the trial. |
| 2019-08-14 | Alaunos Therapeutics | Results Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine alaunos.com ↗
The paper includes data from 31 patients with recurrent glioblastoma (rGBM) treated with Controlled IL-12 (Ad-RTS-hIL-12 plus veledimex, Ad+V). |
| 2019-08-09 | Imunon | Results Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities imunon.com ↗
Those data showed that of the 14 evaluable patients, 100% administered NAC plus the two higher doses of GEN-1 experienced an objective tumor response, defined as a partial or complete response. |
| 2019-06-02 | Alaunos Therapeutics | Results Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting alaunos.com ↗
Controlled IL-12 evaluated as monotherapy in an expanded number of patients confirmed rapid and safe activation of immune system |
| 2019-04-01 | Alaunos Therapeutics | Regulatory Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma alaunos.com ↗
BOSTON , April 01, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults. |
| 2019-03-14 | AstraZeneca | Results AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting astrazeneca.com ↗
Preclinical data for MEDI1191, a novel IL12-based treatment designed for injection directly into tumours, showing potential to drive anti-tumour response for patients with solid tumours both as monotherapy and in combination with anti-PDL1 (Abstract #5017/11) |
| 2019-03-04 | Imunon | Results Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium imunon.com ↗
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the oral presentation of data highlighting the safety, clinical response and translational data from its recently completed OVATION I Study. |
| 2018-11-16 | Alaunos Therapeutics | Results Ziopharm Oncology Provides Controlled IL-12 Update with Positive Data from Phase 1 Trial Presented at Annual Meeting of the Society for Neuro-Oncology alaunos.com ↗
Biopsy data demonstrated that Controlled IL-12 turns immunologically-cold tumors hot based on sustained infiltration of killer T cells which is likely responsible for the improved survival associated with Controlled IL-12 used as monotherapy in patients with rGBM. |
| 2018-10-25 | Inovio Pharmaceuticals | Results Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses inovio.com ↗ |
| 2018-10-24 | Imunon | Results Celsion Announces Progression-Free Survival Data From GEN-1 Phase I Immuno-Oncology Study of Patients with Stage III/IV Ovarian Cancer imunon.com ↗
Single Arm Study Demonstrated a Median Progression-Free Survival (PFS) of 24.3 Months for Patients Treated per Protocol |
| 2018-06-04 | Alaunos Therapeutics | Results Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting alaunos.com ↗ |
| 2018-05-16 | Alaunos Therapeutics | Results Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting alaunos.com ↗
IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients with recurrent glioblastoma |
| 2018-05-15 | Inovio Pharmaceuticals | Results Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial inovio.com ↗
More comprehensive immune analyses demonstrated that PENNVAX-GP (plus IL-12) generated HIV-specific CD4+ T cell and binding antibody response rates close to 100% when delivered with either CELLECTRA ® intramuscular or intradermal devices. |
| 2018-01-24 | Imunon | Regulatory Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer imunon.com ↗
Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer |
| 2017-11-29 | Imunon | Results Celsion Updates Clinical Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients imunon.com ↗
Of the five evaluable patients in the first two cohorts who have been on the study for over one year, only one patient's cancer has progressed after 11.7 months. |
| 2017-11-29 | Imunon | Results Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer imunon.com ↗
The new data demonstrate that intraperitoneally-administered GEN-1 produces an immunologically distinct IL-12 protein that is localized at the tumor site and lasts for up to one week after a single treatment. |
| 2017-11-29 | Imunon | Results Celsion Provides Summary of Research and Development Day Held on October 12, 2017 imunon.com ↗
The lead clinical investigator for the OVATION Study and leading immuno-oncology experts from the Roswell Park Cancer Institute presented their current experience with GEN-1 immunotherapy for the treatment of ovarian cancer. |
| 2017-11-29 | Imunon | Results Celsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium imunon.com ↗
In the first twelve patients dosed in the OVATION Study, GEN-1 plus standard chemotherapy produced impressive clinical results, with no dose limiting toxicities and highly promising efficacy signals in this difficult to treat cancer. |
| 2017-11-29 | Imunon | Results Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin® and Doxil® imunon.com ↗
The results showed that the combination resulted in a statistically significant reduction of tumor burden of greater than 98% compared to control, and a statistically significant 92% reduction in tumor burden compared to Avastin® plus Doxil® alone. |
| 2017-11-29 | Imunon | Results Celsion Corporation Presents Clinical and Preclinical Data for GEN-1 IL-12 Immunotherapy in Ovarian Cancer at the Molecular Medicine TRI-Conference imunon.com ↗
Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a high potential portfolio of innovative cancer treatments, today presented clinical and preclinical data demonstrating the safety, biological activity and clinical benefits of GEN-1, its DNA-based immunotherapy, as a single agent in advanced platinum-resistant and recurrent ovarian cancer patients, at the Molecular Medicine TRI-Conference in San Francisco. |
| 2017-11-29 | Imunon | Results Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer imunon.com ↗
Celsion Corporation (NASDAQ:CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first four patient cohorts in the ongoing Phase 1b OVATION Study. |
| 2017-11-29 | Imunon | Results Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study imunon.com ↗
In the first three patients dosed, GEN-1 plus standard chemotherapy produced excellent results, with no dose limiting toxicities and highly promising efficacy signals leading to successful surgical outcomes. |
| 2017-11-29 | Imunon | Results Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer Presentation imunon.com ↗
The findings demonstrated an overall clinical benefit of 57% for all treatment arms, with a parti |
| 2017-11-29 | Imunon | Results Celsion Announces Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Ovarian Cancer Patients imunon.com ↗
In the first six patients dosed, GEN-1 plus standard chemotherapy produced impressive results, with no dose limiting toxicities and highly promising efficacy signals in this difficult to treat cancer. |
| 2017-11-29 | Imunon | Results Celsion Announces Latest Translational Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients imunon.com ↗
The treatment-related changes in immune activating cytokines and pro-tumor VEGF and IFN- γ levels followed a dose-dependent trend and were predominantly in the peritoneal fluid compartment with little to no changes observed in the patients' systemic circulation. |
| 2017-11-29 | Imunon | Results Celsion Announces Impressive Preclinical Data for its GEN-1 IL-12 Immunotherapy in Combination with Avastin® and Doxil® for Ovarian Cancer imunon.com ↗
The findings represent a statistically significant reduction in tumor burden and disease progression when compared to the combination of Avastin® and Doxil® in a SKOV3 human cell line implanted into immunocompromised (nude) mice. |
| 2017-11-29 | Imunon | Results Celsion Announces Continuing Positive Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients imunon.com ↗
In the first twelve patients dosed in the OVATION Study, GEN-1 plus standard chemotherapy produced impressive results, with no dose limiting toxicities and highly promising efficacy signals in this difficult to treat cancer. |
| 2017-11-29 | Imunon | Results Celsion Announces Continuing Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Stage III and IV Ovarian Cancer Patients imunon.com ↗
In the first nine patients dosed, GEN-1 plus standard chemotherapy produced impressive results, with no dose limiting toxicities and highly promising efficacy signals in this difficult to treat cancer. |
| 2017-11-29 | Imunon | Results Celsion Announces Completion of OVATION Study and Provides Update on its Immunotherapy Trial in Advanced Stage III and IV Ovarian Cancer imunon.com ↗
Of the fourteen patients treated to date, two (2) patients demonstrated a complete response, ten (10) patients demonstrated a partial response and two (2) patients demonstrated stable disease, as measured by RECIST criteria. |
| 2017-11-20 | Alaunos Therapeutics | Results ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting alaunos.com ↗
New data presented shows median overall survival (mOS) of 12.5 months has been sustained for patients treated with Ad-RTS-hIL-12 plus 20mg of veledimex (n=15) at a longer mean follow-up time of 11.1 months as of October 18, 2017. |
| 2017-11-10 | Inovio Pharmaceuticals | Results Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference inovio.com ↗
Interim results presented at the conference show positive safety and tolerability data as well as the generation of hTERT-specific IFN-γ secreting T cells, suggestive of an ability to break immune tolerance. |
| 2017-09-18 | Alaunos Therapeutics | Results ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting alaunos.com ↗
These updated immunohistochemistry data on top of promising survival underscore the possible immunomodulatory benefits of localized and controlled IL-12 and support the advancement of this therapy candidate into a larger outcome study. |
| 2017-06-05 | Alaunos Therapeutics | Results ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting alaunos.com ↗
As of May 24, 2017, the cutoff date for the ASCO presentation, median overall survival (mOS) of all patients receiving intratumoral Ad-RTS-hIL-12 with 20 mg of orally-administered veledimex was maintained at 12.5 months, with a mean follow-up time of 9.2 months. |
| 2017-05-24 | Inovio Pharmaceuticals | Results Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study inovio.com ↗
Notably, amongst the participants receiving PENNVAX-GP vaccine and IL-12 with intradermal immunization, 27 of 28 (96%) participants demonstrated a cellular response and 27 of 28 (96%) demonstrated an HIV env specific antibody response. |
| 2017-04-24 | Matinas BioPharma Nanotechnologies, Inc. | Results Matinas BioPharma Presents Positive Preclinical Data of Orally Available DNA Vaccines at the 27th Annual European Congress of Clinical Microbiology and Infectious Diseases matinasbiopharma.com ↗
From this study, investigators observed that the encochleation of gD and IL-12 plasmids induced 2X greater HSV-specific cytolytic T cell responses than Herpes infection, as well as enhancement of T helper 1 cellular responses and antibody. |
| 2016-11-17 | Alaunos Therapeutics | Results ZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer alaunos.com ↗ |
| 2016-10-10 | Alaunos Therapeutics | Results ZIOPHARM Presents Data Demonstrating Activation of Anti-Tumor Immune Response Using Ad-RTS-hIL-12 in Patients with Advanced Breast Cancer alaunos.com ↗
Results show that Ad-RTS-hIL-12 + 7 days of veledimex consistently elicited production of IL-12 which in turn produced IFNγ. |
| 2016-08-11 | Inovio Pharmaceuticals | Results Inovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen inovio.com ↗
Similarly, in a study arm receiving the vaccine with intramuscular administration in combination with plasmid IL-12, 12 of 13 evaluable subjects (92%) demonstrated strong antibody responses after only two immunizations and 100% produced strong antibody responses after three immunizations. |
| 2016-04-18 | Alaunos Therapeutics | Results ZIOPHARM Announces Two Oral Presentations at ASGCT 19th Annual Meeting alaunos.com ↗
Results demonstrated that survival of mice treated with Ad +V and anti-PD-1 therapy was superior to either treatment alone; |
| 2015-09-18 | Alaunos Therapeutics | Results ZIOPHARM Announces Presentation of Clinical and Preclinical Data From Ad-RTS-IL-12 at CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference alaunos.com ↗
The first poster presentation, titled, "Demonstration of Systemic Antitumor Immunity via Intratumoral Regulated Expression of IL-12 in Advanced Breast Cancer and Melanoma Patients," highlights additional evidence of systemic immune activation with AD-RTS-hIL-12 and veledimex in advanced melanoma and breast cancer patients. |
| 2014-12-03 | Alaunos Therapeutics | Results ZIOPHARM and Intrexon Present Clinical and Preclinical Data From Immuno-Oncology Programs at AACR Tumor Immunology and Immunotherapy Meeting alaunos.com ↗
Interim clinical trial results continue to validate dose-dependent oral veledimex control of the Interleukin-12 (IL-12) gene program module and the rapid reversibility of cytokine expression and associated adverse events in patients upon withdrawal of the activator ligand. |
| 2014-05-22 | Alaunos Therapeutics | Results ZIOPHARM Announces Oral Presentation Highlighting Ad-RTS-IL-12 Results Correlated With Reducing Cancer Stem Cells in the Brain at ASGCT 17th Annual Meeting alaunos.com ↗
When IL-12 expression is "switched on" it rapidly leads to expression and an immune response. |
| 2014-04-08 | Alaunos Therapeutics | Results ZIOPHARM Presents Preclinical Data at AACR Annual Meeting Supporting Controlled DNA-based IL-12 Therapy for Brain Cancer alaunos.com ↗
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of data from a study demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in a glioblastoma (brain cancer) murine model. |
| 2013-12-07 | Alaunos Therapeutics | Results ZIOPHARM Reports Positive Interim Results in Patients With Advanced Melanoma From Ongoing Phase 1/2 Study of Ad-RTS-IL-12 alaunos.com ↗
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with advanced melanoma. |
| 2013-12-06 | Alaunos Therapeutics | Regulatory ZIOPHARM Announces Unanimous Recombinant DNA Advisory Committee (RAC) Approval for Phase 1 Study of Ad-RTS-IL-12 in Subjects With Recurrent or Progressive Glioblastoma alaunos.com ↗
ZIOPHARM Announces Unanimous Recombinant DNA Advisory Committee (RAC) Approval for Phase 1 Study of Ad-RTS-IL-12 in Subjects With Recurrent or Progressive Glioblastoma |
| 2013-10-21 | Alaunos Therapeutics | Results ZIOPHARM and Intrexon Announce Presentation of Data Highlighting Versatility of Novel Gene Expression and Control Technology alaunos.com ↗
This includes the potent anti-cancer effectors IL-12, INFα, and a CTLA-4 decoy, that either could not be delivered or would otherwise be too toxic to be given as intravenous recombinant proteins. |
| 2013-06-01 | Alaunos Therapeutics | Results ZIOPHARM Announces Presentation of Updated Results From Ad-RTS-IL-12 Phase I Study in Advanced Melanoma at the 2013 ASCO Annual Meeting alaunos.com ↗
The study further demonstrated that treatment with Ad-RTS-IL-12 + INXN-1001 was shown to increase intratumoral IL-12 mRNA transcription. |
| 2013-04-09 | Alaunos Therapeutics | Results ZIOPHARM Presents Preclinical Data Supporting DNA-Based IL-12 Therapy for Breast Cancer alaunos.com ↗
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of results from a study in a breast cancer murine model demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12, a viral vector DNA-based therapeutic for the controlled, local expression of IL-12, an important protein for enhancing antitumor immunity. |
| 2012-11-07 | Alaunos Therapeutics | Results ZIOPHARM Oncology Presents Systemic, DNA/Cell Plasmid Therapy Showing Long-Term Persistence and Anti-Tumor Effects at EORTC-NCI-AACR Meeting alaunos.com ↗ |
| 2012-04-03 | Alaunos Therapeutics | Results ZIOPHARM Oncology Presents Compelling Data Showing Palifosfamide Activity in Breast Cancer Models at AACR Meeting alaunos.com ↗
Combined treatment with Ad-RTS-mIL12 + AL and low dose palifosfamide significantly inhibited tumor growth inhibition (~71-90%, p < 0.0 |
| 2012-04-02 | Alaunos Therapeutics | Results ZIOPHARM Oncology Presents Preclinical Data at AACR Meeting Demonstrating Significant Anti-Tumor Activity With Two Immunotherapies Expressed in Vivo by a Regulated Gene System alaunos.com ↗
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today the presentation of preclinical data demonstrating the significant anti-tumor activity of Interleukin-12 (IL-12) and interferon alpha (IFNα), two proteins involved in immune response to cancers, expressed in vivo utilizing a regulated gene system. |
| 2011-06-10 | Alaunos Therapeutics | Regulatory ZIOPHARM Oncology Announces Acceptance of Investigational New Drug Application for ZIN ATI-001 (Ad-RTS-IL-12), a Novel DNA-Based Oncology Therapeutic Candidate alaunos.com ↗
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company's investigational new drug (IND) application to begin clinical study of ZIN ATI -001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL (INXN 2001/1001), in oncology. |
| 2011-06-06 | Alaunos Therapeutics | Results ZIOPHARM Announces Initial Positive Data Presented at 2011 ASCO Annual Meeting from First-Ever Treatment Demonstrating Small Molecule-Controlled Production of Anticancer Protein in Humans alaunos.com ↗
These results were presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3 — 7, in Chicago, IL. |
| 2011-05-20 | Alaunos Therapeutics | Results ZIOPHARM and Intrexon Announce Preclinical Study Results at 2011 ASGCT Meeting from Controlled In Vivo Expression of Genes with Broad and Potent Antitumor Activity alaunos.com ↗
ZIOPHARM and Intrexon Announce Preclinical Study Results at 2011 ASGCT Meeting from Controlled In Vivo Expression of Genes with Broad and Potent Antitumor Activity |
| 2011-05-18 | Alaunos Therapeutics | Results ZIOPHARM Oncology to Present Data at 2011 ASCO Annual Meeting from First-Ever Treatment Demonstrating Small Molecule-Controlled Production of Anticancer Protein in Humans alaunos.com ↗ |
All press releases naming this drug 126 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 126 releases opens the full record — a long page | ||
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interleukin-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001763 ↗ |
| Known as | IL-12 | “The purpose of this study is to see if it is safe and effective to add interleukin-12 (IL-12) to the standard drug combination (paromomycin plus azithromycin) used to treat...” NCT00001128 ↗10“Interleukin-12 (IL-12) facilitates cytolytic T-cell responses, enhances the lytic activity of natural killer (NK) cells, and induces the secretion of interferon gamma...” PMID 11756154 ↗ Jan 2002 “This study will test the safety and effectiveness of a drug called interleukin-12 (IL-12) in fighting severe infectious (other than tuberculosis) caused by a group of bacteria...” NCT00001911 ↗ “Interleukin-12 (IL-12) is a potent immunopotentiator of T-cell function, and has been shown in phase I clinical trials to be tolerable.” PMID 14984966 ↗ Mar 2004 “The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma.” PMID 19243818 ↗ Feb 2009 “ARM II: Patients receive vaccination as in arm I with an admixture of recombinant interleukin-12 (IL-12) on days 1, 22, and 50.” NCT01307618 ↗ “IL-12 (interleukin-12) is a protein found naturally in the body that is thought to boost the immune system.” NCT00000896 ↗ “Patients receive interleukin-12 (IL-12) subcutaneously twice a week (at least 3 days apart) for 6 months.” NCT00019188 ↗ “Interleukin-12 (IL-12) is a cytokine with effects on immune function and hematopoiesis.” PMID 11211153 ↗ Jan 2001 “Interleukin-12 (IL-12) is a central, regulatory cytokine in cell-mediated immunity.” NCT00001763 ↗ “Interleukin-12 (IL-12) DNA adjuvant” NCT02431767 ↗ |
| Known as | NSC # 672423 | “A Phase I Dose-Escalating Study of Recombinant Human Interleukin-12 (NSC # 672423) Administered by Intraperitoneal Infusion” NCT00003439 ↗ |
| Known as | pIL-12 | “plasmid IL-12 (pIL-12)” PMID 32437332 ↗ Jul 2020 |
| Known as | Recombinant Human Interleukin-12 | “A Phase I, Double-Blind, Randomized, Placebo-Controlled Trial of Recombinant Human Interleukin-12 (rhIL-12) in HIV-Infected Subjects With Less Than 50 CD4+ T Cells and Subjects...” NCT00000857 ↗2“recombinant human interleukin-12 (rhIL-12) administered by intraperitoneal infusion” NCT00003439 ↗ “a new schedule of i.v. recombinant human interleukin 12 (rhIL-12)” PMID 10815886 ↗ May 2000 |
| Known as | recombinant interleukin-12 | “Biological: recombinant interleukin-12” NCT00003439 ↗ |
| Known as | rhIL-12 | “A Phase I, Double-Blind, Randomized, Placebo-Controlled Trial of Recombinant Human Interleukin-12 (rhIL-12) in HIV-Infected Subjects With Less Than 50 CD4+ T Cells and Subjects...” NCT00000857 ↗3“recombinant human interleukin-12 (rhIL-12) administered by intraperitoneal infusion” NCT00003439 ↗ “a new schedule of i.v. recombinant human interleukin 12 (rhIL-12)” PMID 10815886 ↗ May 2000 “interleukin-12 (rhIL-12)” NCT00003412 ↗ |
| Action | Activate | “Interleukin-12 may stimulate the white blood cells to kill tumor cells.” NCT00622401 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interleukin-12 (rhIL-12)” NCT00000857 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT00000857 ↗ |